Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kailera Therapeutics, Inc.KLRA · Entity 4435 | See Remarks | April 16, 2026 | April 20, 2026 |
| Translate Bio, Inc.TBIO · Entity 135439 | Chief Operating Officer, CLO · Secretary | September 14, 2021 | September 14, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kailera Therapeutics, Inc.
Report date April 16, 2026 · Filed April 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-04-16 | Direct | 100,000 |
Reported balance
After 2026-04-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-16 · Grant · Acquired 100,000 · Balance 100,000 F1: The options vest and become exercisable as to 25% of the underlying shares on April 16, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-04-16 | Direct | 100,000 |
Reported balance
After 2026-04-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-16 · Grant · Acquired 100,000 · Balance 100,000 F2: The options vest and become exercisable, if at all, as to all of the underlying shares if (i) the average daily closing price of the Company's common stock on Nasdaq during any 30 consecutive calendar-day period during the period beginning October 16, 2026 and ending on April 16, 2030 (the "Performance Measurement Period"), or (ii) the stock price in a change in control transaction that occurs during the Performance Measurement Period, equals or exceeds $40 per share, in each case subject to the Reporting Person's continued service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and become exercisable as to 25% of the underlying shares on April 16, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date.
F2: The options vest and become exercisable, if at all, as to all of the underlying shares if (i) the average daily closing price of the Company's common stock on Nasdaq during any 30 consecutive calendar-day period during the period beginning October 16, 2026 and ending on April 16, 2030 (the "Performance Measurement Period"), or (ii) the stock price in a change in control transaction that occurs during the Performance Measurement Period, equals or exceeds $40 per share, in each case subject to the Reporting Person's continued service through such vesting date.
Translate Bio, Inc.
Report date September 14, 2021 · Filed September 14, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-09-14 transaction · row 1
1 source rowRow 1 · 2021-09-14 · Sale · Disposed 71,833 · Balance 0 F1: As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.39 · Expires 2027-12-21 | Direct | 0 |
Reported balance
After 2021-09-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-09-14 · Sale · Disposed 219,652 · Balance 0 F2: Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share. F3: This option was granted on December 22, 2017. The shares underlying the option became fully vested on March 9, 2021. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.34 · Expires 2028-03-06 | Direct | 0 |
Reported balance
After 2021-09-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-09-14 · Sale · Disposed 69,953 · Balance 0 F2: Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share. F4: This option was granted on March 7, 2018. The shares underlying the option are scheduled to vest over four years, with 25% of the shares vesting on March 7, 2019 and the remainder vesting in equal monthly installments through March 7, 2022. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.95 · Expires 2029-03-07 | Direct | 0 |
Reported balance
After 2021-09-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-09-14 · Sale · Disposed 150,000 · Balance 0 F2: Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share. F5: This option was granted on March 8, 2019. This option will vest as to 25% of the shares on March 8, 2020, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 8, 2023. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.66 · Expires 2030-03-02 | Direct | 0 |
Reported balance
After 2021-09-14 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-09-14 · Sale · Disposed 150,000 · Balance 0 F2: Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share. F6: This option was granted on March 3, 2020. This option will vest as to 25% of the shares on December 11, 2020, and in thirty-six equal monthly installments thereafter as to the remaining shares through December 11, 2023. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.82 · Expires 2031-03-08 | Direct | 0 |
Reported balance
After 2021-09-14 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-09-14 · Sale · Disposed 90,000 · Balance 0 F2: Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share. F7: This option was granted on March 9, 2021. This option will vest as to 25% of the shares on March 9, 2022, and in thirty-six equal monthly installments thereafter as to the remaining shares though March 9, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021.
F2: Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share.
F3: This option was granted on December 22, 2017. The shares underlying the option became fully vested on March 9, 2021.
F4: This option was granted on March 7, 2018. The shares underlying the option are scheduled to vest over four years, with 25% of the shares vesting on March 7, 2019 and the remainder vesting in equal monthly installments through March 7, 2022.
F5: This option was granted on March 8, 2019. This option will vest as to 25% of the shares on March 8, 2020, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 8, 2023.
F6: This option was granted on March 3, 2020. This option will vest as to 25% of the shares on December 11, 2020, and in thirty-six equal monthly installments thereafter as to the remaining shares through December 11, 2023.
F7: This option was granted on March 9, 2021. This option will vest as to 25% of the shares on March 9, 2022, and in thirty-six equal monthly installments thereafter as to the remaining shares though March 9, 2025.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Cerevel Therapeutics Holdings, Inc.
Report date August 01, 2024 · Filed August 05, 2024
Section 16 reporting ended · disclosed 2024-08-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-08-01 transaction · row 1
1 source rowRow 1 · 2024-08-01 · Disposition to issuer · Disposed 45,727 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-08-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-08-01 · Disposition to issuer · Disposed 95,931 · Balance 0 F2: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-08-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-08-01 · Disposition to issuer · Disposed 81,065 · Balance 0 F3: At the Effective Time, (a) 50% of each outstanding award of restricted stock units ("RSUs") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest.
F2: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.
F3: At the Effective Time, (a) 50% of each outstanding award of restricted stock units ("RSUs") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 16, 2026 Filed Apr 20, 2026 21:14 UTC | Kailera Therapeutics, Inc. KLRA · Entity 4435 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001193125-26-164275 · ownership.xml · derivative · entry 2 Burgess Paul D. · CIK 0001744627 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2036-04-16 F2 · derivative.exercise_date: The options vest and become exercisable, if at all, as to all of the underlying shares if (i) the average daily closing price of the Company's common stock on Nasdaq during any 30 consecutive calendar-day period during the period beginning October 16, 2026 and ending on April 16, 2030 (the "Performance Measurement Period"), or (ii) the stock price in a change in control transaction that occurs during the Performance Measurement Period, equals or exceeds $40 per share, in each case subject to the Reporting Person's continued service through such vesting date. Read SEC document |
| April 16, 2026 Filed Apr 20, 2026 21:14 UTC | Kailera Therapeutics, Inc. KLRA · Entity 4435 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001193125-26-164275 · ownership.xml · derivative · entry 1 Burgess Paul D. · CIK 0001744627 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2036-04-16 F1 · derivative.exercise_date: The options vest and become exercisable as to 25% of the underlying shares on April 16, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 16:20 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Disposition to issuerRestricted Stock Units · Derivative | 81,065 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-090787 · ownership.xml · derivative · entry 3 Burgess Paul D. · CIK 0001744627 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 81,065 shares Expires not disclosed F3 · derivative.exercise_price: At the Effective Time, (a) 50% of each outstanding award of restricted stock units ("RSUs") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement. F3 · derivative.exercise_date: At the Effective Time, (a) 50% of each outstanding award of restricted stock units ("RSUs") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement. F3 · derivative.expiration_date: At the Effective Time, (a) 50% of each outstanding award of restricted stock units ("RSUs") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 16:20 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Disposition to issuerStock Option (Right to Buy) · Derivative | 95,931 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-090787 · ownership.xml · derivative · entry 2 Burgess Paul D. · CIK 0001744627 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 95,931 shares Expires not disclosed F2 · derivative.exercise_price: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F2 · price: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F2 · derivative.exercise_date: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F2 · derivative.expiration_date: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 16:20 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Disposition to issuerCommon Stock | 45,727 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-090787 · ownership.xml · nonDerivative · entry 1 Burgess Paul D. · CIK 0001744627 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. Read SEC document |
| January 19, 2024 Filed Jan 23, 2024 17:37 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantRestricted Stock Units · Derivative | 81,065 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-006677 · ownership.xml · derivative · entry 1 Burgess Paul D. · CIK 0001744627 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,065 Underlying: Common Stock · 81,065 shares Expires not disclosed F1 · derivative.exercise_price: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date. F1 · derivative.exercise_date: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date. F1 · derivative.expiration_date: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| December 19, 2023 Filed Dec 21, 2023 20:26 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionRestricted Stock Units · Derivative | 23,847 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-072380 · ownership.xml · derivative · entry 2 Burgess Paul D. · CIK 0001744627 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,847 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represented the contingent right to receive one share of the Issuer's common stock. F1 · kind: In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the "Issuer"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units ("RSUs") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest. F1 · derivative.exercise_date: In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the "Issuer"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units ("RSUs") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest. F1 · derivative.expiration_date: In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the "Issuer"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units ("RSUs") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest. Read SEC document |
| December 19, 2023 Filed Dec 21, 2023 20:26 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionCommon Stock | 23,847 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-23-072380 · ownership.xml · nonDerivative · entry 1 Burgess Paul D. · CIK 0001744627 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,727 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the "Issuer"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units ("RSUs") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest. F2 · price: Each RSU represented the contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 04, 2023 Filed Aug 7, 2023 17:11 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | PurchaseCommon Stock | 21,880 | $22.93 | $501,793.73 |
DisclosureSEC source: 0000950170-23-039165 · ownership.xml · nonDerivative · entry 1 Burgess Paul D. · CIK 0001744627 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,880 F1 · price: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.85 - $22.96. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 16:16 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantRestricted Stock Units · Derivative | 23,847 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-032016 · ownership.xml · derivative · entry 2 Burgess Paul D. · CIK 0001744627 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,847 Underlying: Common Stock · 23,847 shares Expires not disclosed F2 · derivative.exercise_price: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of July 3, 2024, July 3, 2025, July 3, 2026 and July 3, 2027, subject to the Reporting Person's continued service on each such vesting date. F2 · derivative.exercise_date: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of July 3, 2024, July 3, 2025, July 3, 2026 and July 3, 2027, subject to the Reporting Person's continued service on each such vesting date. F2 · derivative.expiration_date: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of July 3, 2024, July 3, 2025, July 3, 2026 and July 3, 2027, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 16:16 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantStock Option (Right to Buy) · Derivative | 95,931 | $0.00 Strike: $31.45 | $0.00 |
DisclosureSEC source: 0000950170-23-032016 · ownership.xml · derivative · entry 1 Burgess Paul D. · CIK 0001744627 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,931 Underlying: Common Stock · 95,931 shares Expires 2033-07-03 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on July 3, 2024, with the remainder vesting in thirty-six (36) monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| September 14, 2021 Filed Sep 14, 2021 19:29 UTC | Translate Bio, Inc. TBIO · Entity 135439 | SaleStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $23.82 | $0.00 |
DisclosureSEC source: 0001209191-21-056057 · doc4.xml · derivative · entry 6 Burgess Paul D. · CIK 0001744627 · Chief Operating Officer, CLO · Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,000 shares Expires 2031-03-08 F2 · kind: Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share. F7 · derivative.exercise_date: This option was granted on March 9, 2021. This option will vest as to 25% of the shares on March 9, 2022, and in thirty-six equal monthly installments thereafter as to the remaining shares though March 9, 2025. Read SEC document |
| September 14, 2021 Filed Sep 14, 2021 19:29 UTC | Translate Bio, Inc. TBIO · Entity 135439 | SaleStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $7.66 | $0.00 |
DisclosureSEC source: 0001209191-21-056057 · doc4.xml · derivative · entry 5 Burgess Paul D. · CIK 0001744627 · Chief Operating Officer, CLO · Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2030-03-02 F2 · kind: Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share. F6 · derivative.exercise_date: This option was granted on March 3, 2020. This option will vest as to 25% of the shares on December 11, 2020, and in thirty-six equal monthly installments thereafter as to the remaining shares through December 11, 2023. Read SEC document |
| September 14, 2021 Filed Sep 14, 2021 19:29 UTC | Translate Bio, Inc. TBIO · Entity 135439 | SaleStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $7.95 | $0.00 |
DisclosureSEC source: 0001209191-21-056057 · doc4.xml · derivative · entry 4 Burgess Paul D. · CIK 0001744627 · Chief Operating Officer, CLO · Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2029-03-07 F2 · kind: Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share. F5 · derivative.exercise_date: This option was granted on March 8, 2019. This option will vest as to 25% of the shares on March 8, 2020, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 8, 2023. Read SEC document |
| September 14, 2021 Filed Sep 14, 2021 19:29 UTC | Translate Bio, Inc. TBIO · Entity 135439 | SaleStock Option (right to buy) · Derivative | 69,953 | $0.00 Strike: $8.34 | $0.00 |
DisclosureSEC source: 0001209191-21-056057 · doc4.xml · derivative · entry 3 Burgess Paul D. · CIK 0001744627 · Chief Operating Officer, CLO · Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 69,953 shares Expires 2028-03-06 F2 · kind: Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share. F4 · derivative.exercise_date: This option was granted on March 7, 2018. The shares underlying the option are scheduled to vest over four years, with 25% of the shares vesting on March 7, 2019 and the remainder vesting in equal monthly installments through March 7, 2022. Read SEC document |
| September 14, 2021 Filed Sep 14, 2021 19:29 UTC | Translate Bio, Inc. TBIO · Entity 135439 | SaleStock Option (right to buy) · Derivative | 219,652 | $0.00 Strike: $7.39 | $0.00 |
DisclosureSEC source: 0001209191-21-056057 · doc4.xml · derivative · entry 2 Burgess Paul D. · CIK 0001744627 · Chief Operating Officer, CLO · Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 219,652 shares Expires 2027-12-21 F2 · kind: Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share. F3 · derivative.exercise_date: This option was granted on December 22, 2017. The shares underlying the option became fully vested on March 9, 2021. Read SEC document |
| September 14, 2021 Filed Sep 14, 2021 19:29 UTC | Translate Bio, Inc. TBIO · Entity 135439 | SaleCommon Stock | 71,833 | $38.00 | $2,729,654.00 |
DisclosureSEC source: 0001209191-21-056057 · doc4.xml · nonDerivative · entry 1 Burgess Paul D. · CIK 0001744627 · Chief Operating Officer, CLO · Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021. F1 · shares: As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021. Read SEC document |
| March 09, 2021 Filed Mar 9, 2021 20:23 UTC | Translate Bio, Inc. TBIO · Entity 135439 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $23.82 | $0.00 |
DisclosureSEC source: 0001209191-21-019299 · doc4.xml · derivative · entry 1 Burgess Paul D. · CIK 0001744627 · Chief Operating Officer, CLO · Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2031-03-09 F1 · derivative.exercise_date: This option will vest as to 25% of the shares on March 9, 2022, and in thirty-six equal monthly installments thereafter as to the remaining shares though March 9, 2025. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 19:49 UTC | Translate Bio, Inc. TBIO · Entity 135439 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $7.66 | $0.00 |
DisclosureSEC source: 0001209191-20-016799 · doc4.xml · derivative · entry 1 Burgess Paul D. · CIK 0001744627 · Chief Operating Officer, CLO · Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2030-03-02 F1 · derivative.exercise_date: This option will vest as to 25% of the shares on December 11, 2020, and in thirty-six equal monthly installments thereafter as to the remaining shares through December 11, 2023. Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 18:10 UTC | Translate Bio, Inc. TBIO · Entity 135439 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $7.95 | $0.00 |
DisclosureSEC source: 0001209191-19-018950 · doc4.xml · derivative · entry 1 Burgess Paul D. · CIK 0001744627 · Chief Legal Officer · Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2029-03-07 F1 · derivative.exercise_date: This option will vest as to 25% of the shares on March 8, 2020, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 8, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.